Lantheus Reports Third Quarter 2024 Financial Results

Rhea-AI Summary

Lantheus (LNTH) reported strong Q3 2024 results with worldwide revenue of $378.7 million, up 18.4% year-over-year. PYLARIFY sales reached $259.8 million (+20.6%) and is on track to exceed $1 billion in 2024. DEFINITY sales grew 14.3% to $77.0 million. The company reported GAAP EPS of $1.79 and adjusted EPS of $1.70. Cash position strengthened to $866.4 million. The company narrowed its FY2024 guidance towards the higher end, projecting revenue of $1.51-1.52 billion and adjusted EPS of $6.65-6.70.

Positive

• Revenue increased 18.4% YoY to $378.7 million
• PYLARIFY sales grew 20.6% to $259.8 million
• DEFINITY sales increased 14.3% to $77.0 million
• Adjusted EPS grew 15.6% to $1.70
• Cash position improved to $866.4 million from $713.7 million
• Operating income increased 19.0% to $133.7 million

Negative

• GAAP EPS decreased 4.8% to $1.79 from $1.88
• GAAP net income declined 0.7% to $131.1 million

Insights

Financial Analyst

The Q3 results showcase robust performance with $378.7M revenue, up 18.4% YoY, primarily driven by PYLARIFY's exceptional growth. The flagship product generated $259.8M in sales, representing a 20.6% increase. Notable is the strong cash position of $866.4M, up significantly from year-end 2023, even after strategic investments.

The guidance narrowing towards the upper end ($1.51-1.52B revenue) signals management's confidence. The CMS rule change for 2025 regarding specialized diagnostic radiopharmaceuticals is particularly significant, as it ensures continued reimbursement stability for PYLARIFY post pass-through status, protecting a important revenue stream.

Key concerns include the SPLASH trial results, where overall survival data remains confounded by crossover patients, potentially complicating regulatory approval pathways.

Medical Research Analyst

The expansion into Alzheimer's diagnostics through NAV-4694 acquisition represents a strategic move into a high-growth market, complementing the existing MK-6240 tau radiodiagnostic. The planned NDA submissions in 2025 (MK-6240) and 2026 (NAV-4694) position Lantheus strongly in the neurological imaging space, particularly important given the growing focus on early Alzheimer's detection and emerging therapies.

The SPLASH trial results for PNT2002 show mixed signals. While meeting the primary rPFS endpoint is positive, the confounded OS data due to crossover presents regulatory challenges. Additional subset analyses may be needed to strengthen the FDA submission package, potentially impacting timeline to market.

• Worldwide revenue of $378.7 million, an increase of 18.4% from third quarter 2023
• GAAP fully diluted earnings per share of $1.79, compared to $1.88 in the third quarter of 2023. Adjusted fully diluted earnings per share of $1.70 compared to $1.47 in the third quarter of 2023
• Company narrows full year 2024 revenue and fully diluted earnings per share guidance towards higher end of the previously issued guidance
• Company applauds CMS' CY25 rule to improve payment for specialized diagnostic radiopharmaceuticals, including PYLARIFY, advancing patient access and care
• Company announced that it expanded its Alzheimer's disease radiodiagnostics portfolio with NAV-4694, a novel, next generation late-stage beta-amyloid imaging agent
  

BEDFORD, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its third quarter ended September 30, 2024.

“PYLARIFY is on track to exceed $1 billion in sales in 2024 and maintain its market leadership and blockbuster status in 2025,” said Brian Markison, Chief Executive Officer of Lantheus. “The success of our flagship diagnostic agents enables us to invest, organically and inorganically in our pipeline to advance our radiopharmaceutical leadership. We are excited about our growing portfolio, especially oncology radiotherapeutics and Alzheimer's disease radiodiagnostics, and will continue to expand our portfolio of late-stage and high potential early-stage product candidates. We are driving growth and shareholder value through operational excellence, financial discipline and prudent capital deployment.”

Summary Financial Results

(in millions, except per share data – unaudited)		Three Months Ended September 30,
			2024				2023			% Change
Worldwide revenue		$	378.7			$	319.9				18.4	%
GAAP net income		$	131.1			$	132.0				(0.7	)%
GAAP fully diluted earnings per share		$	1.79			$	1.88				(4.8	)%
Adj. net income (non-GAAP)		$	124.1			$	103.1				20.4	%
Adj. fully diluted earnings per share (non-GAAP)		$	1.70			$	1.47				15.6	%

Third Quarter 2024

• Worldwide revenue increased 18.4% to $378.7 million compared to the same period in 2023.
• Sales of PYLARIFY were $259.8 million, an increase of 20.6%. Growth was driven by increasing volumes at existing accounts with a slight net price offset as we secured strategic partnerships.
• Sales of DEFINITY were $77.0 million, an increase of 14.3%. Growth was driven by market growth and opportunistic sales due to competitor supply challenges.
• Operating income increased 19.0% to $133.7 million. Adjusted operating income (non-GAAP) increased 18.3% to $165.1 million.
• Fully diluted earnings per share decreased to $1.79, compared to $1.88 in the prior year period. Adjusted fully diluted earnings per share (non-GAAP) increased 15.6% to $1.70, compared to $1.47 in the prior year period.
• Net cash provided by operating activities and free cash flow were $175.1 million and $159.3 million, respectively.

Balance Sheet

• At September 30, 2024, the Company's cash and cash equivalents grew to $866.4 million, compared to $713.7 million at December 31, 2023, even after accounting for the $35.0 million net investment related to the acquisition of RM2 from Life Molecular, a $5 million equity investment in Radiopharm Theranostics as well as a $10 million milestone payment related to the NAV-4694 asset in the third quarter 2024.
• The Company currently has access to up to $350.0 million from a revolving line of credit.

Recent Business Highlights

Radiopharmaceutical Pipeline Progress   

• The Company announced an expansion of its Alzheimer’s disease portfolio in the third quarter, acquiring NAV-4694, a novel, next generation beta-amyloid imaging agent in Phase 3 clinical development. NAV-4694 complements MK-6240, Lantheus’ novel, next-generation, tau radiodiagnostic. The Company plans to submit New Drug Applications for MK-6240 in 2025 and NAV-4694 in 2026.
• With respect to the SPLASH Phase 3 registrational study of PNT2002, the second interim analysis performed at 75% of protocol specified events demonstrated results for radiographic progression free survival (rPFS) and overall survival (OS) that did not materially change from the initial interim analysis conducted at 46% of specified events. PNT2002 is an investigational PSMA-targeted radiotherapeutic for the treatment of patients with metastatic castration-resistant prostate cancer. The SPLASH study met its primary endpoint of rPFS, which was a meaningful and statistically significant improvement for the PNT2002 arm vs. the alternate androgen receptor pathway inhibitor (ARPI) or hormone therapy. The OS results and hazard ratio in the intention-to-treat (ITT) population remain confounded by the overwhelming number of patients who crossed over to receive PNT2002. Crossover adjusted analyses are post-hoc, and the Company will continue to review the data and perform additional sub-set analyses with our partner, Eli Lilly, that may be compelling to the FDA in preparation for an interaction on our path forward.

Other Key Updates

• The Centers for Medicare & Medicaid Services (CMS) released its final Medicare Hospital Outpatient Prospective Payment System (OPPS) rule for calendar year 2025 which included improved payment for specialized diagnostic radiopharmaceuticals to support patient access for Medicare fee-for-service (FFS) beneficiaries. In the rule, innovative diagnostic radiopharmaceuticals, including PYLARIFY, will be paid separately by CMS for traditional Medicare FFS patients in the hospital outpatient setting following the expiry of transitional pass-through payment status. The final rule will take effect January 1, 2025.
  

Full Year 2024 Financial Guidance

	Guidance Issued November 6, 2024	Guidance Issued July 31, 2024
FY 2024 Revenue	$1.51 billion - $1.52 billion	$1.50 billion - $1.52 billion
FY 2024 Adjusted Fully Diluted EPS	$6.65 - $6.70	$6.60 - $6.70

On a forward-looking basis, the Company does not provide GAAP income per common share guidance or a reconciliation of GAAP income per common share to adjusted fully diluted EPS because the Company is unable to predict with reasonable certainty business development and acquisition related expenses, purchase accounting fair value adjustments, and any one-time, non-recurring charges. These items are uncertain, depend on various factors, and could be material to results computed in accordance with GAAP. As a result, it is the Company’s view that a quantitative reconciliation of adjusted fully diluted EPS on a forward-looking basis is not available without unreasonable effort.  

Conference Call and Webcast

As previously announced, the Company will host a conference call and webcast on Wednesday, November 6, 2024, at 8:00 a.m. ET. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events.

A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 days.

The conference call will include a discussion of non-GAAP financial measures. Reference is made to the most directly comparable GAAP financial measures, the reconciliation of the differences between the two financial measures, and the other information included in this press release, our Form 8-K filed with the SEC today, or otherwise available in the Investor Relations section of our website located at www.lantheus.com.

The conference call may include forward-looking statements. See the cautionary information about forward-looking statements in the safe-harbor section of this press release.

About Lantheus Holdings, Inc.

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com. 

Internet Posting of Information

The Company routinely posts information that may be important to investors in the “Investors” section of its website at www.lantheus.com. The Company encourages investors and potential investors to consult its website regularly for important information about the Company. 

Non-GAAP Financial Measures

The Company uses non-GAAP financial measures, such as adjusted net income and its line components; adjusted net income per share - fully diluted; adjusted operating income and free cash flow. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. However, these measures may exclude items that may be highly variable, difficult to predict and of a size that could have a substantial impact on the Company’s reported results of operations for a particular period. Management uses these and other non-GAAP measures internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to employee performance compensation targets. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.  

Safe Harbor for Forward-Looking and Cautionary Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “advance,” “believe,” “continue,” “could,” “driving,” “guidance,” “maintain,” “may,” “on track,” “plan,” “potential,” “predict,” “progress,” “should,” “target,” “will,” “would” and other similar terms. Such forward-looking statements include our guidance for the fiscal year 2024 and our plans to expand our portfolio of late-stage assets and high potential early-stage candidates and are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include: (i) continued market expansion and penetration for our established commercial products, particularly PYLARIFY and DEFINITY, in a competitive environment in which other imaging agents have been approved and are being commercialized, and our ability to clinically and commercially differentiate our products; (ii) our ability to have third parties manufacture our products and our ability to manufacture DEFINITY in our in-house manufacturing facility; (iii) the global availability of Molybdenum-99 (“Mo-99”) and other raw material and key components; (iv) our strategies, future prospects, and our projected growth, including revenue related to our collaboration agreements with POINT Biopharma Global Inc., including our ability to obtain FDA approval for PNT2002 and PNT2003; (v) our ability to satisfy our obligations under our existing clinical development partnerships using MK-6240 or NAV-4694 as a research tool and under the license agreements through which we have rights to MK-6240 and NAV-4694, and to further develop and commercialize MK-6240 and NAV-4694 as approved products; (vi) our ability to successfully execute on our agreements with Perspective Therapeutics, Inc. ("Perspective"), including finalizing the license agreements in the event we exercise our options to do so, the value of our current and any future equity interest in Perspective, and Perspective’s ability to successfully develop its alpha-particle therapy and innovative platform technology; (vii) our ability to successfully identify strategic transaction opportunities, such as our investment in Radiopharm Theranostics Limited ("Radiopharm") common stock, and the value of such current and any future equity interests; (viii) the efforts and timing for clinical development, regulatory approval, adequate coding, coverage and payment and successful commercialization of our product candidates and new clinical applications and territories for our products, in each case, that we or our strategic partners may undertake; (ix) our ability to identify and acquire or in-license additional diagnostic and therapeutic product opportunities in oncology, Alzheimer's disease and other strategic areas and continue to grow and advance our pipeline of products; and (x) the risk and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).

- Tables Follow -

Lantheus Holdings, Inc. Consolidated Statements of Operations (in thousands, except per share data – unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
		2024				2023				2024				2023
Revenues	$	378,734			$	319,946			$	1,142,800			$	942,430
Cost of goods sold		136,608				119,995				403,054				462,756
Gross profit		242,126				199,951				739,746				479,674
Operating expenses
Sales and marketing		43,719				37,399				134,300				106,472
General and administrative		40,516				35,741				135,820				85,163
Research and development		24,148				14,450				132,773				60,883
Total operating expenses		108,383				87,590				402,893				252,518
Gain on sale of assets		—				—				6,254				—
Operating income		133,743				112,361				343,107				227,156
Interest expense		4,903				5,054				14,624				14,978
Investment in equity securities - unrealized gain		(37,325	)			—				(75,492	)			—
Other income		(9,953	)			(52,649	)			(27,785	)			(60,362	)
Income before income taxes		176,118				159,956				431,760				272,540
Income tax expense		45,025				27,999				107,528				49,259
Net income	$	131,093			$	131,957			$	324,232			$	223,281
Net income per common share:
Basic	$	1.89			$	1.93			$	4.69			$	3.27
Diluted	$	1.79			$	1.88			$	4.55			$	3.18
Weighted-average common shares outstanding:
Basic		69,464				68,436				69,193				68,188
Diluted		73,065				70,046				71,331				70,268

Lantheus Holdings, Inc. Consolidated Revenues Analysis (in thousands – unaudited)
		Three Months Ended September 30,												Nine Months Ended September 30,
			2024				2023			% Change					2024				2023			% Change
PYLARIFY		$	259,756			$	215,428				20.6	%		$	791,881			$	621,419				27.4	%
Other radiopharmaceutical oncology			—				848				(100.0	)%			384				2,383				(83.9	)%
Total radiopharmaceutical oncology			259,756				216,276				20.1	%			792,265				623,802				27.0	%
DEFINITY			76,965				67,336				14.3	%			231,629				206,688				12.1	%
TechneLite			20,480				23,272				(12.0	)%			70,380				65,853				6.9	%
Other precision diagnostics			6,282				5,740				9.4	%			18,039				17,002				6.1	%
Total precision diagnostics			103,727				96,348				7.7	%			320,048				289,543				10.5	%
Strategic partnerships and other revenue			15,251				7,322				108.3	%			30,487				29,085				4.8	%
Total revenues		$	378,734			$	319,946				18.4	%		$	1,142,800			$	942,430				21.3	%

Lantheus Holdings, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (in thousands, except per share data – unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
		2024				2023				2024				2023
Net income	$	131,093			$	131,957			$	324,232			$	223,281
Stock and incentive plan compensation		20,366				13,976				54,229				36,335
Amortization of acquired intangible assets		11,908				11,659				31,961				35,132
Campus consolidation costs		23				45				37				3,185
Contingent consideration fair value adjustments		(1,505	)			(500	)			(1,405	)			(9,475	)
Non-recurring refinancing related fees		—				3				—				216
Non-recurring fees		—				(51,789	)			—				(54,523	)
Gain on sale of assets		—				—				(6,254	)			—
Strategic collaboration and license costs		30				—				66,221				—
Investment in equity securities - unrealized gain		(37,325	)			—				(75,492	)			—
Acquisition-related costs		(263	)			169				1,346				507
Impairment of long-lived assets		—				—				—				138,050
ARO Acceleration and other related costs		—				320				—				1,045
Other		805				1,510				2,273				2,194
Income tax effect of non-GAAP adjustments(a)		(1,048	)			(4,256	)			(27,907	)			(61,093	)
Adjusted net income	$	124,084			$	103,094			$	369,241			$	314,854
Adjusted net income, as a percentage of revenues		32.8	%			32.2	%			32.3	%			33.4	%

	Three Months Ended September 30,								Nine Months Ended September 30,
		2024				2023				2024				2023
Net income per share - diluted	$	1.79			$	1.88			$	4.55			$	3.18
Stock and incentive plan compensation		0.28				0.20				0.76				0.52
Amortization of acquired intangible assets		0.16				0.17				0.45				0.50
Campus consolidation costs		—				—				—				0.05
Contingent consideration fair value adjustments		(0.02	)			(0.01	)			(0.02	)			(0.13	)
Non-recurring refinancing related fees		—				—				—				—
Non-recurring fees		—				(0.74	)			—				(0.78	)
Gain on sale of assets		—				—				(0.09	)			—
Strategic collaboration and license costs		—				—				0.93				—
Investment in equity securities - unrealized gain		(0.51	)			—				(1.06	)			—
Acquisition-related costs		—				—				0.02				0.01
Impairment of long-lived assets		—				—				—				1.96
ARO Acceleration and other related costs		—				0.01				—				0.01
Other		0.01				0.02				0.03				0.03
Income tax effect of non-GAAP adjustments(a)		(0.01	)			(0.06	)			(0.39	)			(0.87	)
Adjusted net income per share - diluted	$	1.70			$	1.47			$	5.18			$	4.48
Weighted-average common shares outstanding - diluted		73,065				70,046				71,331				70,268

(a) The income tax effect of the adjustments between GAAP net income and adjusted net income (non-GAAP) takes into account the tax treatment and related tax rate that apply to each adjustment in the applicable tax jurisdiction.

Lantheus Holdings, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (Continued) (in thousands, except per share data – unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
		2024				2023				2024				2023
Operating income	$	133,743			$	112,361			$	343,107			$	227,156
Stock and incentive plan compensation		20,366				13,976				54,229				36,335
Amortization of acquired intangible assets		11,908				11,659				31,961				35,132
Campus consolidation costs		23				45				37				3,185
Contingent consideration fair value adjustments		(1,505	)			(500	)			(1,405	)			(9,475	)
Non-recurring refinancing related fees		—				3				—				216
Non-recurring fees		—				—				—				(2,734	)
Gain on sale of assets		—				—				(6,254	)			—
Strategic collaboration and license costs		30				—				66,221				—
Acquisition-related costs		(263	)			169				1,346				507
Impairment of long-lived assets		—				—				—				138,050
ARO Acceleration and other related costs		—				320				—				1,045
Other		805				1,510				2,273				2,194
Adjusted operating income	$	165,107			$	139,543			$	491,515			$	431,611
Adjusted operating income, as a percentage of revenues		43.6	%			43.6	%			43.0	%			45.8	%

Lantheus Holdings, Inc. Reconciliation of Free Cash Flow (in thousands – unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
		2024				2023				2024				2023
Net cash provided by operating activities	$	175,062			$	116,739			$	387,020			$	192,973
Capital expenditures		(15,808	)			(14,621	)			(35,256	)			(34,486	)
Free cash flow	$	159,254			$	102,118			$	351,764			$	158,487
Net cash (used in) provided by investing activities	$	(67,798	)		$	83,218			$	(219,413	)		$	18,008
Net cash provided by (used in) financing activities	$	1,869			$	108			$	(14,877	)		$	(12,612	)

Lantheus Holdings, Inc. Condensed Consolidated Balance Sheets (in thousands – unaudited)
	September 30, 2024				December 31, 2023
Assets
Current assets
Cash and cash equivalents	$	866,386			$	713,656
Accounts receivable, net		329,336				284,292
Inventory		70,835				64,029
Other current assets		21,998				16,683
Assets held for sale		7,159				7,159
Total current assets		1,295,714				1,085,819
Investment in equity securities		158,791				—
Property, plant and equipment, net		169,512				146,697
Intangibles, net		173,606				151,985
Goodwill		61,189				61,189
Deferred tax assets, net		144,641				150,198
Other long-term assets		46,177				55,261
Total assets	$	2,049,630			$	1,651,149
Liabilities and stockholders’ equity
Current liabilities
Current portion of long-term debt and other borrowings	$	564,713			$	823
Accounts payable		44,914				41,189
Accrued expenses and other liabilities		174,452				145,338
Total current liabilities		784,079				187,350
Asset retirement obligations		23,237				22,916
Long-term debt, net and other borrowings		613				561,670
Other long-term liabilities		61,993				63,321
Total liabilities		869,922				835,257
Commitments and contingencies (See Note 18)
Stockholders’ equity
Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding)		—				—
Common stock ($0.01 par value, 250,000 shares authorized; 70,854 and 69,863 shares issued as of September 30, 2024 and December 31, 2023, respectively)		709				699
Additional paid-in capital		797,430				757,727
Treasury Stock at cost - 1,339 shares as of September 30, 2024 and December 31, 2023		(75,000	)			(75,000	)
Retained earnings		457,735				133,503
Accumulated other comprehensive loss		(1,166	)			(1,037	)
Total stockholders’ equity		1,179,708				815,892
Total liabilities and stockholders’ equity	$	2,049,630			$	1,651,149

Contacts:
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com

Melissa Downs
Senior Director, External Communications
646-975-2533
media@lantheus.com

This press release was published by a CLEAR® Verified individual.

FAQ

What was Lantheus (LNTH) revenue in Q3 2024?

Lantheus reported worldwide revenue of $378.7 million in Q3 2024, representing an 18.4% increase from Q3 2023.

What is Lantheus (LNTH) full year 2024 revenue guidance?

Lantheus narrowed its full year 2024 revenue guidance to $1.51-1.52 billion, towards the higher end of previous guidance.

How much were PYLARIFY sales for Lantheus (LNTH) in Q3 2024?

PYLARIFY sales were $259.8 million in Q3 2024, showing a 20.6% increase, and are on track to exceed $1 billion in 2024.

What was Lantheus (LNTH) adjusted EPS in Q3 2024?

Lantheus reported adjusted earnings per share of $1.70 in Q3 2024, compared to $1.47 in Q3 2023, representing a 15.6% increase.